Conquering cancer with cell therapy

Miltenyi Biotec and ShareLab

Meet and network with experts in Immuno-oncology

ShareLab - Oslo Science Park

Miltenyi Biotec and ShareLab joins forces to invite the local science community to an afternoon dedicated to Cell Therapy and Immuno-oncology! Take the opportunity and meet experts in the field, network and mingle with like-minded scientists in Oslo. And while your at it, treat yourself with some snacks and bubbles as well.We welcome you to the ShareLab premises in Oslo Science Park on December 6th 2022. W﻿e are excited to present a fantastic line-up of speakers for this event, just hear us out:We have invited Group Leader and Principal Investigator Johanna Olweus from the Department of Cancer Immunology, Institute for Cancer Research at Oslo University Hospital to present the pioneering work on new T-cell based concepts for cancer immunotherapy that overcome the major challenge of self-tolerance in cancer. Johanna and her group has a strong translational focus, and Johanna is also in the steering committee for the new Center of Excellence in Oslo: Advanced Center for Cell Therapy. W﻿e are very proud to present Hugh Salter, Chief Scientific Officer at Anocca. Hugh has great experience from the Biopharma industry with previous assignments at AstraZeneca and Moderna Therapeutics. Now he is leading the Scientific development at Anocca, a privately held Swedish biotechnology company founded in 2014 with the mission to establish a unique technology platform for analysis of T-cell biology to unlock the therapeutic potential of T-cell immunity.F﻿inal presentation will be from Head of Clinical Development Lars Moe from ShareLab start-up member Alv B. They say the following about their company and presentation:"Alv B is a biotech start-up developing immunotherapies for companion animals. One of our current projects is to make immune cell therapy for solid tumors in dogs. The primary focus for Alv B is currently to provide immunotherapy to dog cancer patients with spontaneous solid tumours. We are launching a hybrid phase I, multi-centre clinical trial as soon as we get the licence approval from authorities. A secondary goal for our company is to define possible benefits from our dog patient clinical trials to the advantage of human cancer patients. Spontaneous cancer in dogs share many similarities to human cancers both concerning causation, frequency and therapeutic mechanisms. We will be presenting some of the challenges of immune cell therapy in veterinary medicine and our strategy to develop an autologous dendritic cell vaccine for dogs with mammary carcinoma and soft tissue sarcoma." After the presentations there will be a Q&amp;A session where you can ask your questions to the experts, followed by a networking session with snacks and drinks. <h3>Agenda:</h3>15.00: Meet and greet, refreshments and networking15.30: Esben A. Nilssen, Managing Partner ShareLab/Martin Schalén, BioPharma Account, Community and Partner Manager Miltenyi Biotec Nordics - Welcome and introduction15.35: Johanna Olweus, Group Leader and Pricnipal Investigator, Experimental Immunotherapy, Department of Cancer Immunology, Oslo University Hospital - Exploiting T-cell receptors to access novel classes of targets in cancer immunotherapy16:00: Hugh Salter, Chief Scientific Officer, Anocca AB- The Anocca platform for scalable development of TCR-modified T-cell therapies16.25: Lars Moe, Head of Clinical Development, Alv B AS- Autologous dendritic cell as adjuvant therapy for malignant mammary carcinomas and soft tissue sarcomas in dogs16.40: Q&amp;A roundtable discussion17.00: Drinks, refreshments, networking etc.<h3>We are looking forward to meet and network together with you!</h3>//Miltenyi Biotec and ShareLabThis is a research and networking event. We kindly ask additional providers of instrumentation and equipment to not participate in this event as a means to meet potential customers.

<h3>Johanna Olweus, Group Leader and Principal Investigator, Experimental Immunotherapy, Department of Cancer Immunology, Oslo University Hospital </h3>

<h3>H﻿ugh Salter, Chief Scientific Officer, Anocca</h3>

Lars Moe, Head of Clinical Development, Alv B

Our {communityGuidelinesLink} describe the sort of content we prohibit on Eventbrite. If you suspect an event may be in violation, you can report it to us so we can investigate.

To report other categories of prohibited or illegal content, submit {link}

Conquering cancer with cell therapy

More events from Miltenyi Biotec and ShareLab

Discover more events from Miltenyi Biotec and ShareLab, from Science & Tech to other experiences you might love.

Still looking for the right event?

Explore all events in Oslo and filter by date, category, and more to find the perfect fit.

Conquering cancer with cell therapy

More events from Miltenyi Biotec and ShareLab

Discover more events from Miltenyi Biotec and ShareLab, from Science & Tech to other experiences you might love.

You might also like...

Browse more events with different dates, prices, and formats to find your next great experience.

Still looking for the right event?

Explore all events in Oslo and filter by date, category, and more to find the perfect fit.